ArticleThe journal of allergy and clinical immunology. Global2025
Comparing approaches to ordering peanut component-resolved diagnostics to reduce the need for oral food challenges.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peanut component-resolved diagnostics (peanut CRD) is a potentially valuable tool for distinguishing between anaphylactic peanut allergies and milder phenotypes, such as pollen-food allergy syndrome. However, the optimal strategy for integrating CRD into clinical practice remains unclear. Objective: This study aims to evaluate the rates of oral food challenge (OFC) when CRD is ordered: routinely for all patients, selectively on the basis of clinical characteristics, or guided by other peanut biomarkers. Methods: We compared OFC rates between 2 cohorts. Cohort 1 included patients with peanut allergy who received CRD as part of routine testing, regardless of clinical features. In cohort 2, CRD was ordered selectively, depending on factors such as older age, comorbidities, or pollen sensitization. OFC was offered at the physician's discretion in both cohorts. Later, a proposed 2-step clinical algorithm was retrospectively applied to the pooled data to determine patients eligible for OFC. Results: A total of 322 patients (137 in cohort 1 and 185 in cohort 2) participated in the study. OFC rates were lower in the selective testing group (9.7%) and with use of an algorithm (9.5%) than in the group that underwent routine testing (25.5%). The correlation between peanut-specific IgE level and CRD result was high ( Conclusion: Offering CRD selectively on the basis of clinical characteristics and being guided by a 2-step algorithm are more efficient strategies that can reduce rates of OFC to enhance patient safety, optimize health care resource utilization, and reduce costs. As peanut-specific IgE level and CRD result correlate well, testing for Ara h 2 is likely redundant at very high and low ranges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.